171 related articles for article (PubMed ID: 32658630)
1. Reply to T.J.A. Dekker.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Oct; 38(28):3351-3352. PubMed ID: 32658630
[No Abstract] [Full Text] [Related]
2. A new player in the treatment of HER2-positive tumours.
Giannone G; Montemurro F
Lancet Oncol; 2019 Jun; 20(6):748-750. PubMed ID: 31047805
[No Abstract] [Full Text] [Related]
3. Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
Bardia A; Hurvitz SA; Rugo HS
N Engl J Med; 2021 Jul; 385(3):e12. PubMed ID: 34260848
[No Abstract] [Full Text] [Related]
4. Highlights from the 2019 San Antonio Breast Cancer Symposium.
Rugo HS
Clin Adv Hematol Oncol; 2020 Mar; 18(3):157-159. PubMed ID: 32609664
[No Abstract] [Full Text] [Related]
5. Trastuzumab Deruxtecan for Breast Cancer. Reply.
Cortés J; Im SA; Cathcart J
N Engl J Med; 2022 Jun; 386(24):2347. PubMed ID: 35704496
[No Abstract] [Full Text] [Related]
6. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.
Bardia A; Mayer IA; Kalinsky K
N Engl J Med; 2019 Jun; 380(24):2382. PubMed ID: 31189049
[No Abstract] [Full Text] [Related]
8. Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
Modi S; Gambhire D; Cameron D
N Engl J Med; 2022 Sep; 387(12):1145-1146. PubMed ID: 36130006
[No Abstract] [Full Text] [Related]
9. New Drug Approved for HER2-positive Metastatic Breast Cancer.
Aschenbrenner DS
Am J Nurs; 2020 Apr; 120(4):23. PubMed ID: 32218042
[No Abstract] [Full Text] [Related]
10. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Iwata TN; Sugihara K; Wada T; Agatsuma T
PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
12. ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
Lambertini M; Punie K
ESMO Open; 2021 Feb; 6(1):100018. PubMed ID: 33399081
[No Abstract] [Full Text] [Related]
13. Sacituzumab Govitecan in Metastatic Breast Cancer.
Ganguly S; Gogia A
N Engl J Med; 2021 Jul; 385(3):e12. PubMed ID: 34260847
[No Abstract] [Full Text] [Related]
14. Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer.
Stecklein SR; Sharma P
Ann Oncol; 2020 Dec; 31(12):1594-1596. PubMed ID: 33038485
[No Abstract] [Full Text] [Related]
15. Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer.
Cancer Discov; 2020 Apr; 10(4):488. PubMed ID: 32111601
[TBL] [Abstract][Full Text] [Related]
16. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
17. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
[TBL] [Abstract][Full Text] [Related]
18. A closer look at sacituzumab govitecan-hziy.
Bardia A
Clin Adv Hematol Oncol; 2020 Nov; 18(11):715-717. PubMed ID: 33406063
[No Abstract] [Full Text] [Related]
19. Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).
Med Lett Drugs Ther; 2020 Nov; 62(1611):182-184. PubMed ID: 33429416
[No Abstract] [Full Text] [Related]
20. HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer.
Dekker TJA
J Clin Oncol; 2020 Oct; 38(28):3350-3351. PubMed ID: 32658628
[No Abstract] [Full Text] [Related]
[Next] [New Search]
